

08:30 - 09:25 Registration and Coffee

09:25 - 09:30 Welcome

09:30 - 11:00 What's new in NETs? ENETS guidelines update (new recommendations applied to interactive cases), UK epidemiology and genetics
Chairs: Andrea Frilling (London) & Martin Weickert (Coventry)

09:30 Midgut NETs – *Mohid Khan (Cardiff)*

09:50 Pancreatic NETs - *Judith Cave (Southampton)*

10:10 Bronchial NETs - *Wasat Mansoor (Manchester)*

10:30 Update on national incidence data from Public Health England (PHE) - *John Ramage (London)*

10:45 Where NETs fit in with the 100,000 genome project – *Louise Izatt (London)*

11:00 - 11:30 Coffee, Exhibition and Posters

11:30 - 12:45 Management of Pheochromocytoma/Paraganglioma

Chairs: Maralyn Druce (London) & David Scott-Coombes (Cardiff)

11:30 Clinician viewpoint – *Simon Aylwin (London)*

11:55 Special considerations in the management of patients with familial Pheochromocytoma/Paraganglioma syndromes - *Scott Akker (London)*

12:20 Imaging viewpoint - *Shaunakk Navalkisoor (London)*

12:45 - 13:00 AGM

13:00 - 14:00 Lunch, Exhibition & Posters

14:00 - 14:45 Debate: This house believes management of patients with NETs should be undertaken by.....

Chair: Christos Toumpanakis (London)

14:00 Oncologists
Nick Reed (Glasgow)

14:05 Gastroenterologists
Martyn Caplin (London)

14:10 Endocrinologists
Ashley Grossman (Oxford)

14:15 Discussion with audience participation

14:45 - 15:30 Open clinical session

Chairs: Barbara King (London) & Nickie Jervis (London)

14:45 Survey of the Somatostatin Analogue use in the UK
Mike Tadman (Oxford)

15:00 An exploration of psychological symptoms in Carcinoid Syndrome
Liz Friend (Basingstoke)

14:45 - 15:30 Translational Science Session

Chair: Chrissie Thirlwell (London)

14:45 Whole-exome sequencing (WES) of samples from patients with advanced pancreatic neuroendocrine tumours (pNETs) with exceptional responses vs. poor responders to targeted therapies
Jorge Barriuso (Manchester)

15:05 Immunotherapy in solid tumours, determination of immune-response and where this might lead in NETs
Christian Ottensmeier (Southampton)

15:30 - 16:00 Coffee, Exhibition and Posters

16:00 - 16:30 Oral Communications

Chairs: John Ayuk (Birmingham) & Mark Pritchard (Liverpool)

16:00 Netazepide, a gastrin/CCK₂ receptor antagonist, can eradicate gastric neuroendocrine tumours in patients with autoimmune chronic atrophic gastritis – *Malcom Boyce (London)*

16:10 Tumour Size is Not a Reliable Criterion for Management of Patients with Non-Secreting Pancreatic Neuroendocrine Tumours: Results of a Large, Multi-Centre, Operative Cohort – *Logan Mills (Coventry)*

16:20 Efficacy and Safety of Telotristat Etiprate in Patients with Carcinoid Syndrome not Adequately Controlled by Somatostatin Analog Therapy: Analysis of the Ongoing TELESTAR Extension Period – *Martin Caplin (Slough)*

16:30 - 17:00 International Speaker & Trials update

Chair: Tim Meyer (London)

16:30 NET therapy on the horizon - evaluating the current evidence - *Kjell Öberg (Uppsala, Sweden)*

17:00 Trials update – *Juan Valle (Manchester)*

17:20 - 17:30 Prize giving & closing

17:30 Wine & cheese